Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
1,248,774
result(s) for
"Tumors"
Sort by:
Biomarkers in Medicine
Biomarkers in Medicine is a comprehensive guide to understanding the current and future status of biomarkers. The book features 27 chapters focusing on disease biomarkers for diseases such as cancer, neurodegenerative diseases, cardiac diseases, metabolic conditions and much more. This book supplies readers with the unique insight of experts in multiple specialties in medicine and life sciences who have extensive experience in diagnostics and clinical laboratories. The book includes case studies and practical examples from different classes of biomarkers on different platforms, including new data for biomarkers in different therapeutic indications. In addition to presenting biomarker information, each chapter covers the relevant pathology and also emphasizes on preclinical and clinical manifestation of the disease process. Clinicians managing patients or clinical trials, clinical researchers, clinical laboratories, diagnostic companies, regulatory agencies, medical school graduate students, academic students, and the general public involved in healthcare delivery will all benefit from information presented in this book.
eBook
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
As compared with placebo, extended-release lanreotide (120 mg every 28 days) was associated with delayed disease progression in patients with nonfunctional, slowly progressing neuroendocrine tumors. Progression-free survival at 24 months was 65% with lanreotide and 33% with placebo.
Neuroendocrine tumors are rare neoplasms,
1
,
2
with an annual incidence of 5 cases per 100,000 people in the United States.
1
More than 50% of cases involve tumors originating in the gastrointestinal system or pancreas, and patients commonly have distant metastases at diagnosis.
1
Since many of these patients have inoperable disease, medical therapy is often initiated to control disease progression. Treatment may also be required to relieve symptoms arising from the overproduction of amines or peptide hormones in functioning tumors.
Few medical treatments for advanced neuroendocrine tumors have been approved on the basis of their antiproliferative effects (i.e., efficacy in inhibiting . . .
Journal Article
Death be not proud : a memoir
The father of a seventeen-year-old who died of a brain tumor describes his son's courage in the face of certain death.
Book
177LuLu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
There are currently no standard first-line treatment options for patients with higher grade 2–3, well-differentiated, advanced, gastroenteropancreatic neuroendocrine tumours. We aimed to investigate the efficacy and safety of first-line [177Lu]Lu-DOTA-TATE (177Lu-Dotatate) treatment.
NETTER-2 was an open-label, randomised, parallel-group, superiority, phase 3 trial. We enrolled patients (aged ≥15 years) with newly diagnosed higher grade 2 (Ki67 ≥10% and ≤20%) and grade 3 (Ki67 >20% and ≤55%), somatostatin receptor-positive (in all target lesions), advanced gastroenteropancreatic neuroendocrine tumours from 45 centres across nine countries in North America, Europe, and Asia. We used interactive response technologies to randomly assign (2:1) patients to receive four cycles (cycle interval was 8 weeks ± 1 week) of intravenous 177Lu-Dotatate plus intramuscular octreotide 30 mg long-acting repeatable (LAR) then octreotide 30 mg LAR every 4 weeks (177Lu-Dotatate group) or high-dose octreotide 60 mg LAR every 4 weeks (control group), stratified by neuroendocrine tumour grade (2 vs 3) and origin (pancreas vs other). Tumour assessments were done at baseline, week 16, and week 24, and then every 12 weeks until disease progression or death. The primary endpoint was progression-free survival by blinded, independent, central radiology assessment. We did the primary analysis at 101 progression-free survival events as the final progression-free survival analysis. NETTER-2 is registered with ClinicalTrials.gov, NCT03972488, and is active and not recruiting.
Between Jan 22, 2020, and Oct 13, 2022, we screened 261 patients, 35 (13%) of whom were excluded. We randomly assigned 226 (87%) patients (121 [54%] male and 105 [46%] female) to the 177Lu-Dotatate group (n=151 [67%]) and control group (n=75 [33%]). Median progression-free survival was 8·5 months (95% CI 7·7–13·8) in the control group and 22·8 months (19·4–not estimated) in the 177Lu-Dotatate group (stratified hazard ratio 0·276 [0·182–0·418]; p<0·0001). During the treatment period, adverse events (of any grade) occurred in 136 (93%) of 147 treated patients in the 177Lu-Dotatate group and 69 (95%) of 73 treated patients in the control group. There were no study drug-related deaths during the treatment period.
First-line 177Lu-Dotatate plus octreotide LAR significantly extended median progression-free survival (by 14 months) in patients with grade 2 or 3 advanced gastroenteropancreatic neuroendocrine tumours. 177Lu-Dotatate should be considered a new standard of care in first-line therapy in this population.
Advanced Accelerator Applications, a Novartis Company.
Journal Article
The cancer chronicles : unlocking medicine's deepest mystery
Deftly excavating and illuminating decades of investigation and analysis, rooted in every discipline from evolutionary biology to game theory and physics, Johnson explores what we know--and what we still don't--about cancer, and why a cure remains such a slippery goal.
Book
The reason you're alive
After sixty-eight-year-old David Granger crashes his BMW, medical tests reveal a brain tumor that he readily attributes to his wartime Agent Orange exposure. He wakes up from surgery repeating a name no one in his civilian life has ever heard--that of a Native American soldier whom he was once ordered to discipline. David decides to return something precious he long ago stole from the man he now calls Clayton Fire Bear. It may be the only way to find closure in a world increasingly at odds with the one he served to protect. It may also help him to finally recover from his wife's untimely demise. As David confronts his past to salvage his present, a poignant portrait emerges: that of an opinionated and good-hearted American patriot fighting like hell to stay true to his red, white, and blue heart, even as the country he loves rapidly changes in ways he doesn't always like or understand. Hanging in the balance are Granger's distant art-dealing son, Hank; his adoring seven-year-old granddaughter, Ella; and his best friend, Sue, a Vietnamese American who respects David's fearless sincerity. Through the controversial, wrenching, and wildly honest David Granger, Matthew Quick offers a no-nonsense but ultimately hopeful view of America's polarized psyche.